- Home
- PPBT vs CYCN Comparison
PPBT vs CYCN Comparison
Compare PPBT & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- CYCN
- Stock Information
- Founded
- PPBT 2010
- CYCN 2018
- Country
- PPBT Israel
- CYCN United States
- Employees
- PPBT N/A
- CYCN N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- PPBT Health Care
- CYCN Health Care
- Exchange
- PPBT Nasdaq
- CYCN Nasdaq
- Market Cap
- PPBT 7.4M
- CYCN 7.6M
- IPO Year
- PPBT N/A
- CYCN N/A
- Fundamental
- Price
- PPBT $0.71
- CYCN $1.40
- Analyst Decision
- PPBT Strong Buy
- CYCN
- Analyst Count
- PPBT 1
- CYCN 0
- Target Price
- PPBT $33.00
- CYCN N/A
- AVG Volume (30 Days)
- PPBT 21.8M
- CYCN 1.0M
- Earning Date
- PPBT 11-14-2025
- CYCN 11-07-2025
- Dividend Yield
- PPBT N/A
- CYCN N/A
- EPS Growth
- PPBT N/A
- CYCN N/A
- EPS
- PPBT N/A
- CYCN N/A
- Revenue
- PPBT N/A
- CYCN $2,855,000.00
- Revenue This Year
- PPBT N/A
- CYCN N/A
- Revenue Next Year
- PPBT N/A
- CYCN N/A
- P/E Ratio
- PPBT N/A
- CYCN N/A
- Revenue Growth
- PPBT N/A
- CYCN N/A
- 52 Week Low
- PPBT $0.53
- CYCN $1.27
- 52 Week High
- PPBT $13.95
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- PPBT 45.98
- CYCN 34.27
- Support Level
- PPBT $0.71
- CYCN $1.28
- Resistance Level
- PPBT $0.89
- CYCN $2.23
- Average True Range (ATR)
- PPBT 0.13
- CYCN 0.17
- MACD
- PPBT 0.01
- CYCN -0.04
- Stochastic Oscillator
- PPBT 17.37
- CYCN 11.32
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.